ArticleJournal of neuro-oncology2011
The combined effects of oncolytic reovirus plus Newcastle disease virus and reovirus plus parvovirus on U87 and U373 cells in vitro and in vivo.
Article in Journal of neuro-oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- Case Report: Complete response with combination oncolytic virus immunotherapy in a patient with stage IV renal cell carcinoma-a promising innovative approach.Frontiers in oncology · 2025Article
- Oncolytic virotherapy for metastatic breast cancer - a case report.Frontiers in oncology · 2023Article
- Effective Treatment of Glioblastoma Multiforme With Oncolytic Virotherapy: A Case-Series.Frontiers in oncology · 2020Article
- Letter to the Editor on "Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL".Stem cell research & therapy · 2017Article
- Pathogen response-like recruitment and activation of neutrophils by sterile immunogenic dying cells drives neutrophil-mediated residual cell killing.Cell death and differentiation · 2017Article
- Targeting Autophagy for Oncolytic Immunotherapy.Biomedicines · 2017Review
- Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity.World journal of methodology · 2016Review
- Naturally occurring reoviruses for human cancer therapy.BMB reports · 2015Review
- Replicating poxviruses for human cancer therapy.Journal of microbiology (Seoul, Korea) · 2015Review
- Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy.Molecular therapy oncolytics · 2015Article
- Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No?Journal of Cancer · 2015Review
- Brain Tumor Immunotherapy: What have We Learned so Far?Frontiers in oncology · 2015Review
- Current status of gene therapy for brain tumors.Translational research : the journal of laboratory and clinical medicine · 2013Article
- Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia.BioResearch open access · 2012Article
- Oncolytic Virotherapy for Relapsed, IDH-Mutant, Grade 3 Astrocytoma: A New Promising Approach - A Case Report.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous results had documented oncolytic capacity of reovirus, parvovirus and Newcastle disease virus (NDV) on several tumor cell types. To test whether combinations of these viruses may increase this capacity, human U87- and U373-glioblastoma cells, in vitro or xenografted into immuno-compromised mice, were subjected to simultaneous double infections and analyzed. Our results show that reovirus (serotype-3) plus NDV (Hitcher-B1) and reovirus plus parvovirus-H1 lead to a significant increase in tumor cell killing in vitro in both cell lines (Kruskal-Wallis test, P < 0.01) and in vivo. Immunofluorescence and flow cytometry analyses demonstrated the simultaneous replication of the viruses in nearly all cells (>95%) after combined infection. These data thus indicate that a synergistic anti-tumor effect can be achieved by the combined infection with oncolytic viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.